Abstract
Sarcomas represent a rare and heterogeneous disease and the prognosis of patients remains poor, with a disease-free survival at 5 years of less than 10%. Only a few chemotherapeutic agents, such as doxorubicin and ifosfamide, have been identified to be active with response rates above 20%. The concept of angiostatic therapy in combination with proapoptotic biomodulators and chemotherapeutics has not been evaluated in these patients. Therefore, the efficacy of low-dose trofosfamide in combination with the peroxisome proliferator-activated receptor-γ-agonist, pioglitazone, and the selective cyclooxygenase-2 inhibitor, rofecoxib, was evaluated in a pilot study. Six patients with advanced sarcoma received a combination of oral pioglitazone plus rofecoxib and, after 14 days, oral trofosfamide. The therapy was administered continuously daily. Four patients received the triple combination as maintenance therapy; three of them achieved stabilization of disease. Two patients received the combination as relapse therapy; however, it failed to stop disease progression. Side effects were generally mild and hospitalization was not necessary. This new triple combination of low-dose trofosfamide, pioglitazone, and rofecoxib may represent a feasible new alternative in the palliative treatment of sarcoma patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
SS Yoon NH Segal AB Olshen et al. (2004) ArticleTitleCirculating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma Ann Oncol 15 1261–1266 Occurrence Handle15277268 Occurrence Handle1:STN:280:DC%2BD2cznt1Wltw%3D%3D Occurrence Handle10.1093/annonc/mdh309
P Sarraf E Mueller D Jones et al. (1998) ArticleTitleDifferentiation and reversal of malignant changes in colon cancer through PPARγ Nat Med 4 1046–1052 Occurrence Handle9734398 Occurrence Handle1:CAS:528:DyaK1cXlvFGju7c%3D Occurrence Handle10.1038/2030
J Masferrer (2001) ArticleTitleApproach to angiogenesis inhibition based on cyclooxygenase-2 Cancer J 7 IssueIDSuppl 3 S144–S150 Occurrence Handle11779086
T Vogt C Hafner K Bross et al. (2003) ArticleTitleAntiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors Cancer 15 2251–2256
A Reichle K Bross T Vogt et al. (2004) ArticleTitlePioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft-tissue sarcoma Cancer 101 2247–2256 Occurrence Handle15470711 Occurrence Handle1:CAS:528:DC%2BD2cXhtVKisbnL Occurrence Handle10.1002/cncr.20574
C Kollmannsberger W Brugger JT Hartmann et al. (1999) ArticleTitlePhase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma Anticancer Drugs 10 453–456 Occurrence Handle10477164 Occurrence Handle1:CAS:528:DyaK1MXltFCht7s%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kasper, B., Ho, A. & Egerer, G. A new therapeutic approach in patients with advanced sarcoma. Int J Clin Oncol 10, 438–440 (2005). https://doi.org/10.1007/s10147-005-0514-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10147-005-0514-9